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Abstract: This review presents the latest available international data
for lung cancer incidence, mortality and survival, emphasizing the
established causal relationship between smoking and lung cancer. In
2002, it was estimated that 1.35 million people throughout the world
were diagnosed with lung cancer, and 1.18 million died of lung
cancer—more than for any other type of cancer. There are some key
differences in the epidemiology of lung cancer between more de-
veloped and less developed countries. In more developed countries,
incidence and mortality rates are generally declining among males
and are starting to plateau for females, reflecting previous trends in
smoking prevalence. In contrast, there are some populations in less
developed countries where increasing lung cancer rates are predicted
to continue, due to endemic use of tobacco. A higher proportion of
lung cancer cases are attributable to nonsmoking causes within less
developed countries, particularly among women. Worldwide, the
majority of lung cancer patients are diagnosed after the disease has
progressed to a more advanced stage. Despite advances in chemo-
therapy, prognosis for lung cancer patients remains poor, with
5-year relative survival less than 14% among males and less than
18% among females in most countries. Given the increasing inci-
dence of lung cancer in less developed countries and the current lack
of effective treatment for advanced lung cancers, these results
highlight the need for ongoing global tobacco reform to reduce the
international burden of lung cancer.
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Lung cancer continues to be the leading cause of cancer-related deaths worldwide.1 Despite improvements in sur-
vival for many other types of cancer in recent years, 5-year
survival for lung cancer has remained relatively poor, mainly
because by the time a diagnosis is made, lung cancer is often
well advanced and treatment options are limited.2–4
The most important risk behavior for lung cancer is
tobacco smoking. The relationship between smoking and
lung cancer is one of the most thoroughly investigated issues
in biomedical research,5 and compelling evidence has built up
since the middle of the twentieth century to indicate that
smoking is the predominant causal factor for lung cancer.6–10
A large number of studies have found that smokers have a 15-
to 30-fold increased risk of developing lung cancer compared
with nonsmokers.9 There is also sufficient evidence to con-
clude that exposure to second-hand smoke (commonly known
as ‘passive smoking’) can cause lung cancer.6,11
However not all lung cancers are due to smoking, and it is
likely that the proportion of lung cancer patients who have never
smoked may increase in the future.12,13 Exposure to indoor radon
(a naturally occurring radioactive gas) is considered to be the
second most important environmental risk factor for lung cancer
behind tobacco smoke in the United States,14 and was recently
estimated to be responsible for 9% of all lung cancer deaths in
Europe.15 A family history of lung cancer has been shown to
result in a twofold increase in lung cancer risk, independent of
smoking.16,17 Air pollution, pre-existing diseases of the lungs
such as tuberculosis or pneumonia, high doses of radiation, and
exposure to industrial or chemical carcinogens such as asbestos,
silica, and arsenic have also been associated with an increased
risk of developing lung cancer.5,12,18,19 Factors such as house-
hold air pollution from cooking and heating fumes appear to
play a greater role in the etiology of lung cancer for nonsmokers
within less developed countries, especially among women.20–22
The purpose of this review is to describe current inter-
national patterns in lung cancer incidence, mortality and
survival, including recent trends, along with a discussion of
the impact of smoking on the observed data. (Throughout this
article, lung cancer has been defined as codes C33–C34 using
the International Classification of Diseases, 10th revision
[ICD-10].23) An international perspective has been provided
wherever possible; however, when detailed information was
only available for a specific country (for example, incidence
by stage), data from that country is presented alone.
LUNG CANCER INCIDENCE
An estimated 1.35 million people were diagnosed with
lung cancer worldwide during 2002 (12% of all invasive can-
cers),1 an increase of about 110,000 compared with the number
of lung cancers diagnosed in 2000.24 About 71% (or about
960,000) of these lung cancer diagnoses were among males,1
with age-standardized rates (using the World Health Organiza-
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tion World Standard population)25 of 40 and 13 new cases per
100,000 population for males and females respectively.26
Globally, lung cancer has been the most common
cancer diagnosed each year since 1985.1 Lung cancer had a
higher incidence among males worldwide than any other
cancer, followed by prostate cancer (more common in devel-
oped countries) and stomach cancer (particularly in develop-
ing countries). Among females, lung cancer was the fourth
most diagnosed cancer, behind breast cancer, cervical cancer
(mostly in developing countries), and colorectal cancer.1
For both sexes, the estimated number of lung cancer cases
diagnosed in more developed countries during 2002 was similar
to that in less developed countries.1 However, after allowing for
differences in population size and age structures, lung cancer
incidence rates were around twice as high in more developed
countries (61/100,000 among males and 19/100,000 among
females) compared with less developed countries (29/100,000
among males and 10/100,000 among females).26
Sex-specific incidence rates varied substantially between
countries (Fig. 1). For males, estimated lung cancer incidence
rates ranged from 104/100,000 in Hungary to less than
5/100,000 in many African countries (such as Kenya). The
highest estimated rate for females was in the United States
(40/100,000 population) compared with a rate of between 2 to
3/100,000 in a range of less developed countries including India,
Algeria, Kenya, and Iran (Table 1).26
Text Box 1
GLOBOCAN data
The main source of data used in this article was GLOBOCAN
2002. GLOBOCAN is a database constructed by the World
Health Organization (WHO) which contains estimates of
incidence, mortality and prevalence data for different types
of cancer for every country as at 2002.26 GLOBOCAN 2002
was published in 2004, and remains the most recent source of
international cancer data currently available. Data from
GLOBOCAN can be reported in terms of more developed
and less developed countries. More developed countries
included those in Europe and North America along with
Australia, New Zealand, and Japan, whereas less developed
countries were defined as those in Africa, Central and South
America, Asia (excluding Japan), and all other island nations
(i.e., those in the Caribbean, Melanesia, Micronesia, and
Polynesia).27 Care should be taken when interpreting any
comparisons of international data. For example, the accuracy
of cancer data in GLOBOCAN varies from region to region.
Incidence and mortality data for countries including Austra-
lia, Canada, and the United Kingdom were based on national
data collections. In contrast, national estimates for many coun-
tries throughout Asia (including China and India) were based on
cancer registries that only cover part of the population, whereas
in Africa estimates were often obtained by averaging results
from neighboring countries.26 Similarly, the accuracy of prema-
ture mortality data reported later in this article ranges from a
relative uncertainty of less than 1% in countries with compre-
hensive death registration systems up to 25% in countries where
the collection of mortality data is limited.28
Incidence by Age
Worldwide during 2002, 5% of lung cancer cases were
diagnosed among people aged 0 to 44 years, 14% in the 45 to
54 age group, 25% in the 55 to 64 age group, and 55% among
those aged 65 years and over.26 These proportions were fairly
uniform for both sexes.
Age-specific lung cancer incidence rates were between
1.5 to 2.3 times higher for more developed countries com-
pared with less developed countries within each age group.
There was also a significantly higher proportion of lung
cancer patients aged 65 years and over at diagnosis within
more developed countries (62% compared with 49% in less
developed countries).26 This primarily reflects the higher life
expectancy and different age distribution in more developed
countries compared with less developed countries.
Although current smokers are at an increased risk of
developing lung cancer compared with nonsmokers within every
age group (20–25 times higher among males and 10–12 times
higher among females across most age groups),7 there does not
appear to be any clear link between median age at diagnosis and
smoking status.12,29,30 It is possible that the apparent parity of
age at diagnosis by smoking status may stem from biologic
differences between lung cancer among never smokers com-
pared with lung cancer among smokers.12,30
Text Box 2
Worldwide smoking prevalence
In 2005, it was estimated that around 1.25 billion adults
throughout the world were smokers–around 1 billion men
and 250 million women.31 This represented approximately
35% of men and 22% of women in more developed coun-
tries, compared with 50% of men and 9% of women in less
developed countries.31 Smoking rates were highest for men
in Afghanistan (82%), Yemen (77%), and Djibouti (75%)
and for women in the Cook Islands (71%), Nauru (59%), and
Guinea (47%).31
Incidence by Histology
Lung cancers can be divided into two main types: small
cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). SCLCs are the most aggressive form of the dis-
ease, having greater potential to metastasis than other types of
lung cancer. Nearly all patients (over 95%) diagnosed with
SCLC are current or ex-smokers.32
NSCLCs are a heterogeneous group, of which the most
common subtypes are squamous cell carcinomas and adenocar-
cinomas. Squamous cell carcinomas are also predominantly
linked to smoking.33 These tumors tend to grow in the center of
the lung and have the capacity to grow to large sizes.34 Adeno-
carcinomas usually occur in the periphery of the lung.34 Al-
though it is the most common type of lung cancer seen in
nonsmokers,19 smoking has been increasingly associated as a
cause of adenocarcinoma in more recent years.6,35
The distribution of lung cancer incidence by histol-
ogy and sex for selected countries is shown in Table 2.
Within each of these countries, squamous cell carcinoma
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comprised a much higher proportion of lung cancers diag-
nosed among males than females, whereas adenocarci-
noma comprised a greater proportion of lung cancers
diagnosed among females compared with males. Among
males, squamous cell carcinoma was the most common
histologic type of lung cancer in Korea (46%), France
(41%) and the United Kingdom (40%), whereas adenocar-
cinoma was the most common type in the United States
(31%), Canada (31%), Sweden (30%), and Australia
(29%). With the exception of the United Kingdom (where
28% of lung cancer cases among females were squamous
cell carcinomas), adenocarcinomas made up the greatest
proportion of lung cancers among females for all of the
countries shown (ranging from 38% in the United States up
to 69% in Japan).36 Small cell cancers comprised between
14% (Australia and Japan) to 17% (Korea and the United
Kingdom) of lung cancers among males, and between 9%
(Japan) to 22% (United Kingdom) of lung cancers among
females.
Incidence by Stage
Lung cancer is typically asymptomatic in its early
stages of development, and even when symptoms appear,
they are usually nonspecific.37 As a result, the majority of
lung cancer patients are diagnosed after the disease has
progressed to a more advanced stage. In the United States
between 1996–2003, only 16% of lung cancer cases were
localized when diagnosed (compared with 91% for prostate
cancer, 80% for melanoma and 61% for female breast can-
cer), 35% were regional and 41% were distant, with the
remaining 8% unstaged.38 Females were slightly more likely
than males to be diagnosed with localized lung cancer (18%
and 15% respectively), whereas a higher proportion of
males had distant metastases at diagnosis (43% males, 39%
females).38
Incidence Trends
The estimated number of lung cancer cases rose by
51% worldwide between 1985 and 2002, with a larger in-
crease among females (76%) compared with males (44%).1
After adjusting for population increases and ageing, age-
standardized rates decreased slightly (3%) among males
over this period, whereas rates increased (22%) among
females.1
Lung cancer incidence rates peaked among males in
North America, Australia, New Zealand, and many coun-
tries in North-Western Europe during the 1980s and have
since been declining.27,39,40 In contrast, the incidence rates
FIGURE 1. International variation in age-stan-
dardized lung cancer incidence rates (per
100,000 population) in 2002. Notes: 1. Rates
age-standardized to the WHO World Standard
Population.25 Source: GLOBOCAN 2002, Inter-
national Agency for Research on Cancer
(IARC).26 2. Lung cancer incidence rates for fe-
males are represented in the top map and for
males in the bottom map. 3. The numbers in
brackets shown in the legend signify how many
countries are included in that incidence range.
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for males in many Southern and Eastern European coun-
tries, Japan and China, and for females from most devel-
oped countries, either continue to increase or have recently
begun to plateau (Figure 2).27,39 – 41 Although trend data is
scarce for less developed countries, there is some evidence
that lung cancer rates among females in Latin America are
increasing,42 and the incidence of lung cancer is predicted
to increase substantially throughout Asia and Africa, par-
ticularly among males.20
As a result of these differing trends, the global burden
of lung cancer has shifted towards less developed countries.
In 1980 it was estimated that 31% of new lung cancers were
diagnosed in developing countries, but by 2002 this had risen
to about 50%.1
TABLE 1. Age-Standardizeda Lung Cancerb Incidence and Mortality Rates (Per 100,000 Population) by Sex for Selected
Countries, 2002
Males Females
Incidence Mortality Incidence Mortality
Cases ASR Deaths ASR Cases ASR Deaths ASR
World 965,241 39.5 848,132 34.9 World 386,891 13.5 330,786 11.5
More developed
countries
481,950 61.0 423,507 53.2 More developed
countries
194,731 18.9 161,472 15.2
Less developed
countries
481,029 28.7 422,681 25.5 Less developed
countries
191,192 10.4 168,481 9.2
More developed countries
Hungary 6461 103.7 5,773 92.3 United States 86,024 40.1 65,792 30.0
Poland 19,478 90.4 16,354 75.9 Canada 8096 34.8 6808 28.5
Belgium 6,518 83.9 6235 78.5 Denmark 1515 32.8 1475 30.8
Russia 53,654 73.4 50,658 69.5 United Kingdom 15,424 27.8 13,390 23.7
Belarus 3825 72.3 3482 66.0 Hungary 2276 27.1 2097 24.4
United States 118,873 69.2 94,640 54.8 New Zealand 607 22.8 574 21.2
Italy 30,384 64.8 26,990 56.3 Australia 2679 18.8 2246 15.4
Canada 12,552 62.6 11,032 54.7 Poland 4534 15.9 3960 13.5
Spain 17,983 61.7 16,253 54.7 Sweden 1253 15.7 1197 14.3
France 23,044 57.5 21,760 52.6 Japan 18,889 13.8 15,257 10.9
United Kingdom 24,300 54.3 21,959 48.6 Belgium 1189 13.3 1052 11.1
Denmark 2011 50.8 2045 51.0 Italy 6784 11.8 5788 9.5
Australia 5565 44.5 4936 39.3 France 4507 9.6 4465 8.8
Japan 47,564 43.2 41,110 36.9 Russia 8909 7.3 8743 6.9
New Zealand 974 42.1 911 39.3 Spain 2038 5.9 1870 5.2
Sweden 1736 23.7 1896 25.5 Belarus 466 5.0 421 4.7
Less developed countries
Kazakhstan 4794 85.0 4095 73.7 China 126,718 20.9 109,059 18.1
Uruguay 1202 65.4 1017 53.3 Cuba 1229 18.1 1227 18.1
Philippines 10,823 55.8 10,064 51.8 Philippines 3358 15.0 3120 14.0
Turkey 12,862 52.3 11,884 48.4 Kazakhstan 1085 12.7 947 11.1
China 269,650 47.2 231,301 40.9 Thailand 3026 11.4 2858 10.8
Cuba 2826 44.7 2699 42.6 South Africa 1203 8.2 1,099 7.6
Thailand 6429 28.1 6070 26.6 Brazil 5498 7.9 5524 8.0
South Africa 3043 27.4 2788 25.2 Mexico 2633 7.6 2567 7.4
Brazil 13,635 24.0 12,728 22.5 Indonesia 6227 7.5 5736 7.0
Indonesia 15,432 22.3 14,299 20.7 Uruguay 160 7.2 158 6.4
Mexico 5622 19.2 5477 18.8 Zimbabwe 195 6.6 190 6.5
Algeria 1552 18.5 1510 18.1 Turkey 1572 5.8 1453 5.3
Zimbabwe 353 13.8 344 13.4 Egypt 772 3.1 747 3.0
India 35,495 9.9 30,706 8.7 Iran 506 2.4 466 2.3
Egypt 1886 9.5 1837 9.3 Kenya 176 2.3 167 2.2
Iran 1502 8.0 1386 7.5 Algeria 209 2.3 205 2.2
Kenya 296 4.6 288 4.5 India 8046 2.1 6934 1.9
a Rates age-standardized to the WHO World Standard Population.25
b Based on International Classification of Diseases, Version 10 (ICD-10)23 codes C33–C34–malignant neoplasms of the trachea, bronchus, and lung.
Data source: GLOBOCAN 2002, International Agency for Research on Cancer (IARC).26
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Lung cancer incidence and mortality trends closely
reflect patterns in smoking prevalence from 20 to 30 years
earlier,37,44,45 due to the characteristically long latency period
between when a person starts to smoke and when they are
diagnosed with or die of lung cancer.46 The link between lung
cancer trends and smoking behavior is further demonstrated
TABLE 2. Distribution of Lung Cancer by Histological Type and Sex for Selected Countries, 1998–2002
Small Cell (%) Squamous (%) Adenocarcinoma (%) Other/Unspecified (%) Microscopically Verified (%)
Males
Australia 14.2 27.2 29.1 27.9 82.6
Canada 15.0 30.0 31.3 22.5 78.7
France 15.7 40.8 26.0 16.2 95.6
Japan 14.2 32.5 40.8 7.3 74.8
Korea 17.1 45.7 26.2 9.4 74.7
Sweden 15.5 29.2 30.4 22.6 97.7
UK (excluding Wales) 17.3 39.6 18.0 23.6 66.6
USA 15.2 26.9 31.0 25.7 88.1
Females
Australia 16.7 16.8 37.2 28.0 73.8
Canada 17.1 17.9 41.1 22.8 78.4
France 16.3 19.6 44.3 18.2 94.6
Japan 9.0 11.4 68.5 4.9 70.1
Korea 11.8 16.5 58.7 10.6 62.0
Sweden 17.5 17.1 39.7 23.1 97.1
UK (excluding Wales) 22.4 28.1 23.5 24.4 62.6
USA 18.4 17.9 37.6 24.8 87.0
Data source: Cancer Incidence in Five Continents, Vol IX (IARC).36
FIGURE 2. Recent trends in lung cancer incidence by sex for selected countries/registry areas, 1980–2004. Data sources:
Australian Institute of Health and Welfare (Australia); Public Health Agency of Canada (Canada); Thames Cancer Registry
(South-East England); National Cancer Registry of Ireland (Ireland); National Cancer Centre (Japan); National Cancer Institute
(USA). Notes: 1. y axis represents ‘Incidence rate per 100,000 population per year’ and x axis represents ‘Year’. 2. Incidence
rates have been age-standardized to the WHO World Standard Population.25 3. Trends modeled using Joinpoint software (ver-
sion 3.0), National Cancer Institute.43
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by changes in the distribution of the histologic subtypes of
lung cancer over time.
Modifications to cigarette design (particularly the shift
to filter cigarettes in the 1960s and 1970s), cigarette compo-
sition, and smoking behavior are widely believed to be the
major reasons behind the relative increase in the incidence of
adenocarcinoma compared with other types of lung can-
cer.47–50 Smoke from lower yield (i.e., low tar, low nicotine,
or filtered) cigarettes tends to be inhaled more deeply, result-
ing in a higher concentration of carcinogens in the outer areas
of the lungs where adenocarcinomas tend to form. In addi-
tion, the tobacco blends used in cigarette manufacturing were
changed to include higher levels of nitrates, which have also
been linked to the development of adenocarcinoma.47–49 The
rapid increase in adenocarcinoma means that it has now
overtaken squamous cell carcinoma as the most common
form of lung cancer diagnosed among males in some coun-
tries, and has continued to be the dominant type of lung
cancer diagnosed among females.40,47
LUNG CANCER SURVIVAL
Although there is some variation in lung cancer sur-
vival rates between countries, the prognosis for people diag-
nosed with lung cancer remains poor worldwide, with 5-year
relative survival typically between 6 to 14% among males
and 7 to 18% among females (Table 3).
One reason for the low lung cancer survival rates
relates to the lack of observable symptoms for early stage
lung cancer. Lung cancers diagnosed based on symptoms
alone are usually well advanced and treatment options are
limited.37,51,52 Surgical resection remains the most effective
treatment for early localized tumors,53,54 but only a minority
of lung cancers are diagnosed at that stage. Another probable
reason for poor survival among lung cancer patients is the
effect of smoking, in that smoking-related comorbidities such
as cardiovascular diseases or chronic obstructive pulmonary
disease may have an additional negative impact on surviv-
al.55,56 There is also some evidence that current or previous
smoking reduces the effectiveness of radiotherapy or chemo-
therapy when treating lung cancer.57,58
International comparisons of lung cancer survival data
can be problematic (see Text Box 3). However, even after
considering these caveats, survival for lung cancer patients
diagnosed in Japan seems to be higher than in other more
developed countries (Table 3), followed by North America,
whereas generally lower survival rates were reported for
European countries.
Data on cancer survival among less developed coun-
tries is limited,59 with 5-year survival for lung cancer aver-
aging around 9% in developing countries for both males and
females combined (based on areas where population cancer
registry data was available).1 Although this is considerably
lower than the survival reported for some developed regions
such as Japan and North America, it is similar to the average
5-year survival for lung cancer of just under 11% for all
persons that was recently estimated for Europe.60
Text Box 3
Interpreting survival data
Reported differences in lung cancer survival between
countries do not necessarily translate into real differences,
but may be due to characteristics of the underlying data.
Some of the factors to consider when comparing survival
results include completeness of population coverage, data
quality (including linkage to mortality records), consis-
tency of analysis methodology, the time period that the
estimates are from, demographic differences (e.g., age,
sex, socioeconomic status), tumor-related characteristics
such as histology and stage at diagnosis, and health system
issues including access to treatment.67,68
Lung cancer survival is generally, but not always, better
for females and for younger patients.69–74 Although the exact
mechanisms for potential differences in survival by sex and
age at diagnosis remain unclear, possible explanations in-
clude gender-related differences in tumor biology and/or




Country Yr Method Male Female
Australia 1992–1997 Cohort 11.0 (10.6–11.4) 14.0 (13.3–14.7)
Austria 1990–1994 Cohort 13.4 (11.0–16.4) 16.0 (11.9–21.6)
Canada 1997–2002 Period 13.3 (12.6–14.0) 18.5 (17.5–19.4)
Czech
Republic
1990–1994 Cohort 6.3 (5.0–7.8) 8.2 (5.1–13.1)
Denmark 1990–1994 Cohort 6.1 (5.5–6.7) 5.9 (5.3–6.6)
England 1990–1994 Cohort 7.4 (7.2–7.6) 7.7 (7.4–8.0)
Estonia 1990–1994 Cohort 6.8 (5.5–8.4) 11.9 (9.0–15.9)
Finland 1990–1994 Cohort 7.8 (7.2–8.6) 10.9 (9.4–12.7)
France 1990–1994 Cohort 13.1 (11.6–14.8) 15.9 (12.2–20.7)
Germany 1990–1994 Cohort 10.8 (9.4–12.5) 10.5 (8.0–13.7)
Iceland 1990–1994 Cohort 8.0 (5.2–12.4) 10.6 (7.0–16.0)
Italy 1990–1994 Cohort 9.8 (9.4–10.2) 10.5 (9.6–11.5)
Japan 1993–1996 Cohort 20.7 (21.1–20.3) 27.6 (28.2–27.0)
Netherlands 1990–1994 Cohort 11.7 (10.9–12.6) 12.4 (10.8–14.2)
New Zealand 1994–2003 Cohort 9.5 (8.8–10.4) 11.1 (10.1–12.1)
Norway 1990–1994 Cohort 8.0 (7.2–8.9) 10.5 (9.2–12.0)
Poland 1990–1994 Cohort 6.1 (5.3–6.9) 6.8 (5.7–8.2)
Scotland 1990–1994 Cohort 7.0 (6.5–7.6) 6.8 (6.2–7.4)
Slovakia 1990–1994 Cohort 6.9 (6.2–7.8) 12.0 (9.9–14.5)
Slovenia 1990–1994 Cohort 8.0 (6.8–9.3) 9.3 (7.2–12.0)
Spain 1990–1994 Cohort 12.4 (11.6–13.2) 12.8 (10.4–15.8)
Sweden 1990–1994 Cohort 8.5 (7.8–9.2) 11.5 (10.4–12.6)
Switzerland 1990–1994 Cohort 9.7 (7.9–11.9) 16.2 (12.5–20.9)
USA 1996–2003 Cohort 13.0 (12.8–13.2) 17.4 (17.0–17.8)
Wales 1990–1994 Cohort 8.0 (7.3–8.7) 7.5 (6.5–8.5)
Data sources: Australia,61 Canada,62 Europe,63 Japan,64 New Zealand,65 USA.66
Confidence intervals are provided to indicate the precision of the estimate, but are
not meant for comparative purposes (see Text Box 3).
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hormonal factors,75,76 whereas some commentators have sug-
gested that any survival advantage among younger lung
cancer patients may be due to more aggressive treatment
compared with older patients.74,77
Prognosis for SCLC is usually inferior compared with
NSCLC. In the United States, the 5-year relative survival rate
by type of lung cancer was about 17% for patients with
NSCLC and only 6% for those diagnosed with SCLC be-
tween 1996–2003.38 Similar differences in survival by his-
tology have been reported for Canada, Australia, and
throughout Europe.78–80
Survival for patients with lung cancer has shown only
modest, if any, improvement over the last two or three
decades, both in terms of all lung cancers combined38,80–82
and within the individual histology groups.39,80,83,84 However,
it is anticipated that the development of more effective and
well-tolerated chemotherapy drugs (such as gemcitabine and
pemetrexed), in conjunction with an improved understanding
of the biology of lung tumors, will help improve survival
rates and quality of life for both NSCLC and SCLC patients
within the foreseeable future.85,86
The results from several large, recent studies have
indicated that nonsmokers who develop lung cancer have a
better prognosis than smokers, after taking into account other
factors such as demographic characteristics and existing co-
morbid diseases.30,55,87 That a differential exists in lung
cancer survival between smokers and nonsmokers after ad-
justing for histology, stage, comorbidities and treatment most
likely suggests a biologic difference in cancer progression
(possibly as a result of late mutational effects, immune
suppression or oxidative tissue damage) between smoking-
related lung cancer and other forms of lung cancer.55
LUNG CANCER MORTALITY
Lung cancer is the leading cause of cancer-related
deaths worldwide. In 2002 there were about 1.18 million
deaths caused by lung cancer internationally,1 an increase of
over 70,000 deaths since 2000.24 Lung cancer deaths caused
almost 18% of total cancer mortality1,88 and around 2% of all
mortality worldwide during 2002.88
Nearly three-quarters (72% or 850,000) of lung cancer
deaths throughout the world during 2002 occurred among
males,1 equating to an age-standardized rate (World Health
Organization World Standard population)25 of 35/100,000
population for males compared with a rate of 11/100,000
population for females.26 Worldwide lung cancer was clearly
the leading cause of cancer-related deaths among males, after
stomach cancer and liver cancer, and ranked second among
females behind breast cancer.1 However, in some countries
(notably the USA since 198789 and more recently some
European countries including the UK, Sweden, and Den-
mark90) lung cancer has overtaken breast cancer as the lead-
ing cause of cancer death among females.
Similarly to incidence, the estimated average age-stan-
dardized mortality rates (MR) for lung cancer during 2002 in
more developed countries (53/100,000 among males and
15/100,000 among females) were about twice that of less
developed countries (26/100,000 among males and 9/100,000
among females).26 For males, the MR was highest in Hungary
(92/100,000 population) compared with rates of less than
5/100,000 in parts of Africa (such as Kenya), whereas among
females the MR varied from 31/100,000 in Denmark to below
2/100,000 in India (Table 1).26
The MR and incidence rate for lung cancer are generally
quite similar within a given population, which is indicative of
the poor survival prospects of most lung cancer patients.27 The
ratio of MR: incidence rate was the same (0.89) for both males
and females in less developed countries, but was lower for
females (0.81) compared with males (0.87) within more devel-
oped countries,26 reflecting the slightly better survival prospects
of females living in more developed countries.
A higher proportion of lung cancer deaths were attrib-
utable to smoking than for any other disease.91 It has been
estimated that nearly three quarters (71%) of lung cancer
deaths worldwide were caused by smoking in 2000.91 By
2015, this would result in a projected 1.18 million smoking-
related lung cancer deaths per year.88 The influence of smok-
ing on lung cancer was particularly strong in more developed
countries, causing 91% of lung cancer deaths among males
and 71% among females. In less developed countries, the
contribution of smoking to lung cancer deaths was substan-
tially lower (66% for males and 25% for females),91 further
emphasizing the greater impact of other risk factors for lung
cancer (such as coal smoke and occupational exposure to
carcinogens) in places like Asia and Africa.92
Text Box 4
Do people with lung cancer always die specifically
from lung cancer?
There is a common perception that almost all people diag-
nosed with lung cancer die of lung cancer.55 However be-
tween 20 and 40% of early stage lung cancer patients die of
other causes,55 which are often smoking-related comorbidi-
ties such as ischemic heart disease or stroke.93,94 In Australia
lung cancer patients were more than four times as likely to
die of a noncancer cause compared with the general popu-
lation,93 whereas in the United States lung cancer patients
who died of other causes were more likely to be males and in
the older age groups.95
Premature Mortality
Due to the poor survival for lung cancer patients, the
main burden of lung cancer is due to premature mortality
rather than long-term illness. Estimates from the Global
Burden of Disease Study96 reveal that in 2002, lung cancer
caused nearly 11 million years of life lost. Lung cancer was
the leading cause of cancer-related premature mortality
among males (20%) and ranked second for females (10%)
behind breast cancer (17%). In contrast, lung cancer was
estimated to be responsible for approximately 233,000 years
lost due to disability during 2002, comprising 11% of cancer-
related years lost due to disability among males and 3%
among females.96
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In terms of premature mortality from all causes, lung
cancer was estimated to be responsible for 1.6% of pre-
mature mortality among males and 0.7% among females in
2002.96 There was substantial variation in these propor-
tions between regions (Figure 3). Lung cancer was most
prominent as a cause of premature mortality among both
males and females in North America (6.7% and 6.8% of
total premature mortality, respectively) and among males
in Western Pacific Region A (6.8%); however, lung cancer
caused very little premature mortality in Africa (less than
0.1% for both sexes).96 This is most likely as a result of
smoking prevalence in Africa being historically lower in
comparison to many developed countries (particularly
among females),98,99 combined with shorter life expect-
ancy and much higher MRs from infectious diseases such
as HIV/AIDS (which was estimated to have caused almost
60% of premature mortality throughout Africa compared
with less than 4% in North America96).
Mortality Trends
Trends in lung cancer MRs between 1980 to 2005 for
24 selected countries (with sufficient quality and quantity of
data) are shown in Figure 4. The close association between
lung cancer incidence and mortality is again evidenced by the
similarities in the incidence and MR trends within particular
countries (compare with Figure 2).
Mortality rates for males were decreasing significantly
in all of the countries shown except for Bulgaria, where the
rates were stable, and China, Israel, Romania, and South
Korea where rates were rising. The greatest decreases were
recorded in the United Kingdom and Australia, where the
lung cancer MRs among males had been dropping by 3.5%
per year between 1991 and 2004 and 3.2% per year between
1994 and 2003, respectively. In contrast, the largest increase
was in South Korea, where the yearly MR rose by 9.9% per
year from 1985 to 1994, and then continued to grow by 1.8%
per year between 1994 and 2004.
Among females, lung cancer MRs were increasing in
most of the countries included in Figure 4. Exceptions were
stable trends in Bulgaria, Canada, Denmark, and the USA, and
decreasing trends in Hong Kong, Japan, Russia, Singapore, and
the UK. The decreases were greatest in Hong Kong and Russia,
where the lung cancer MRs had been falling by 2.3% and 2.0%
per year, respectively, since 1990. The largest rises were occur-
ring in Spain (5.3% increase per year between 1999–2004).
Female lung cancer MRs are also continuing to rise rapidly in
France (4.3% per year between 1993–2003) and the Netherlands
(4.2% per year between 1994–2004).
Of the countries shown in Figure 4, the most recent
lung cancer mortality trends by sex can be summarized into
the following 5 general patterns:
Y An increasing trend for both sexes eg, China, Israel,
Romania, South Korea;
Y An increasing trend for females and a decreasing trend
for males e.g., Australia, France, Germany, Greece,
Hungary, Ireland, Italy, Netherlands, New Zealand,
Poland, Spain, Sweden;
Y A decreasing trend for both sexes e.g., Hong Kong,
Japan, Russia, Singapore, United Kingdom;
Y A decreasing trend for males and stable for females e.g.,
Canada, Denmark, United States; and,
Y Stable trends for both sexes e.g., Bulgaria.
Since a previous report on country-specific trends between
1971 to 1995,100 lung cancer MRs for both sexes are now
decreasing in Japan, trends for males have begun to decrease in
several European countries, Canada and the USA, trends have
stabilized for females in Canada, Denmark, and the USA, and
rates for women have started to decrease in the UK.
Lopez et al.101 suggested a model consisting of four
stages to explain the link between past smoking behavior
in a population and lung cancer mortality trends (see Text
Box 5). Although the model may not exactly describe the
FIGURE 3. Percent of total Years of Life Lost (YLLs) due to lung cancer, by region, 2002. Data source: World Health Organi-
zation (WHO).96 Note: Western Pacific Region A includes Australia, Brunei, New Zealand, Japan and Singapore. Western
Pacific Region B incorporates all other countries in this region, including China, Mongolia, Republic of Korea and the Pacific
Island nations.97
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FIGURE 4. Recent trends in lung cancer mortality by sex for selected countries, 1980–2005 Data source: World Health Orga-
nization (WHO).102 Notes: (1) Countries were selected on the basis of having lung cancer mortality data of sufficient quality
(at least 80% of all deaths registered, except China, which was based on a sample of less than 10% of all deaths) and quan-
tity (average of at least 300 lung cancer deaths per year for males and 250 deaths per year for females). (2) y axis represents
’Incidence rate per 100,000 population per year’ and x axis represents ‘Year.’ (3) Rates age-standardized to the WHO World
Standard Population.25 (4) Trends modeled using Joinpoint software (version 3.0), National Cancer Institute.43
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relationship experienced between smoking and lung cancer
in every country, it provides a framework for understand-
ing how the health effects of smoking become evident after
a delay of a few decades.101
Text Box 5
Evolution of the worldwide lung cancer epidemic
Researchers from the World Health Organization have sug-
gested a four stage model based on tobacco consumption to
explain broad differences in lung cancer trends around the
world.101 The model emphasizes the need for sustained
commitment at every stage to reduce tobacco use.103
• Stage 1—Includes countries where the smoking epidemic
has not yet taken off but the population is vulnerable to the
tobacco industry. Lung cancer is rare, with incidence rates
generally comparable to a nonsmoking population. Exam-
ples include many countries throughout Africa.
• Stage 2—There is a rapid rise in smoking among
males, with smoking also becoming more common
among females. The proportion of ex-smokers is low,
and tobacco control is limited, with smoking typi-
cally seen as a socially acceptable behavior. Lung
cancer becomes increasingly common, particularly
for males. Many countries in Asia, North Africa, and
South America are at this stage.
• Stage 3—Characterized by a public perception that
smoking is a health hazard, allowing the introduction
of comprehensive tobacco control legislation. Smok-
ing rates are falling for males and have typically
plateaued among females. Lung cancer rates continue
to rise sharply before peaking towards the end of this
phase. Countries in Eastern and Southern Europe are
current examples.
• Stage 4 —Smoking rates for both males and females
continue to decline, although smoking remains more
common among males and differences in smoking by
socio-economic status will persist and perhaps even
widen. Legislation allowing a smoke-free environ-
ment becomes a key issue. Lung cancer rates for
males continue to decrease, but may still be rising
among women in response to the later peak in smok-
ing prevalence for females. Many developed coun-
tries are now at this stage, including North America,
North-Western Europe and Australia.
Age-period-cohort modeling using lung cancer mortal-
ity data from European Union countries and North America
has found that lung cancer MRs have been declining for
males under 65 years of age and had either reached a plateau
or were starting to fall among older males.104,105 Mortality
rates for females were generally increasing across all age
groups in European countries, but were falling or had stabi-
lized among women aged under 65 in the United Kingdom,
Ireland, Canada, and the United States.104,105 Some evidence
is also starting to emerge that lung cancer MRs may be
declining among younger females (20–44 years) in several
other countries throughout Europe.106 In countries where lung
cancer MRs were decreasing for either males or females, the
cohort results generally show that MRs were decreasing
among successive generations,104,105 although there seems to
have been some moderation in these trends within the United
States among people born after 1950.107
ISSUES AFFECTING THE FUTURE
INTERNATIONAL BURDEN OF LUNG CANCER
Despite the declining or plateauing trends in lung can-
cer rates in some countries, experts are predicting that lung
cancer will continue to be a major cause of death throughout
the world within the foreseeable future, particularly due to the
ageing of the global population. It is estimated that by 2030
lung cancer will be the sixth most common cause of death,
compared with its current ranking of ninth.88
The shift towards a higher proportion of lung cancer
cases occurring in developing countries appears set to con-
tinue.27,44 It is thought that by the year 2025, 85% of the
world’s smokers will live in less developed countries,108 and
by 2030 it is expected that around 70% of all tobacco-related
deaths (including lung cancer) will occur in the world’s poor
and middle income nations, compared with the current esti-
mate of 50%.31,109
Smoking patterns in China are likely to strongly
influence the global burden of lung cancer within the next
10 to 20 years. China consumes about one in three of all
the cigarettes produced in the world,110 due to a combina-
tion of its huge population and the high prevalence of
smoking among Chinese males (67%).31 Lung cancer MRs
are already increasing among both sexes, in all age groups,
and in both urban and rural areas of China.110 If current
smoking patterns persist in China, a massive rise in smok-
ing-related deaths is predicted.110 –112
The prevalence of smoking among young people is
another important international issue, particularly the increas-
ing use of tobacco products among girls in many coun-
tries.31,113,114 The American Cancer Society has reported that
nearly 100,000 children and adolescents become addicted to
tobacco worldwide every day,31 and recent data from the
Global Youth Tobacco Survey indicates that about one out of
every 6 (17%) school students aged 13 to 15 have either
smoked cigarettes and/or used other tobacco products.113
These issues highlight the ongoing need for targeted
tobacco control in an attempt to permanently arrest the
worldwide spread of lung cancer,44,115–117 especially within
less developed countries. Tobacco control programs have
proven to be successful in reducing smoking prevalence and
uptake in some developed countries, including the USA and
Australia,118–120 although further opportunities for progress in
tobacco control remain among inveterate smokers121 and
people in high-risk smoking groups, such as those who are
socioeconomically disadvantaged.122–124 The World Health
Organization has recently released a report which promotes
six key tobacco control strategies.125 These strategies are
monitoring of tobacco use and prevention policies; protecting
people from tobacco smoke; offering help to quit tobacco use;
warning about the dangers of tobacco; enforcing bans on
Youlden et al. Journal of Thoracic Oncology • Volume 3, Number 8, August 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer828
tobacco advertising, promotion and sponsorship; and raising
taxes on tobacco.125
Although optimism remains that the impending lung
cancer epidemic can be averted,31,44,115 this will only occur if
there is “. . . political will to tackle tobacco, and appropriate
funding proportional to the magnitude of the epidemic, and
individual commitment by smokers to quit.”31
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